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biosynthetic pathways were primarily in focus at the 
beginning of antimetabolite era. The first metabolic 
pathway modulated in oncology and virology was one-
carbon metabolism. This pathway targets folate, which 
acts as a single-carbon donor critical for purine ring 
formation [2].
Endogenous purine nucleosides are involved in 
essential cellular processes such as DNA and RNA 
synthesis, cell signaling, enzyme regulation and 
metabolism [3]. Their synthetic, chemically modified 
analogs have been developed to mimic physiological 
molecules and exploit cellular metabolism. The analogs 
can be incorporated into DNA or RNA and inhibit cancer 
cell and virus replication. In addition to their incorporation 
into nucleic acids, purine nucleoside analogs can interact 
with and inhibit essential enzymes such as DNA and RNA 
polymerases, kinases, ribonucleotide reductase, DNA 
methyltransferases and purine nucleoside phosphorylase 
[3].
Gertrude Elion and George Hitchings, Nobel Prize 
Laureates for Physiology and Medicine in 1988 [4-6], 
developed 6-Mercaptopurine (6-MP) that was shown to 
induce complete, albeit temporary, remissions of acute 
leukemia in children when very few other treatment 
options were available. 6-MP was approved by the US 
Food and Drug Administration for this indication in 1953, 
two years after its first synthesis.
The classic antimetabolite strategy provided the 
basis for chemotherapy regimens that are still used 
today. Obvious limitation when nucleotide pathways are 
generally targeted is the lack of a sufficient therapeutic 
window. Selectivity towards cancer cells remains a huge 
problem. Therefore, achieving selectivity by modulating 
nucleotide pathways is the major aim in the future 
research in this field [4].
Some of purine nucleoside analogues are used against 
viral infection, which primarily does not attack central 
nervous system (CNS), but is linked to neuroinflammation 
and cognitive impairment [7-10]. Therefore, therapeutic 
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Abstract: Purine nucleoside analogs have been in clinical 
use for almost 50 years. At the beginning developed as 
antiviral agents, later their efficacy was demonstrated in 
cancer treatment, especially hematological malignances. 
The approval of new purine nucleoside analogs by US 
Food and Drug Administration (FDA) over the past decade 
implies that the interest for these drugs still exists. Here, 
we review new nucleoside analogs that are currently in 
preclinical or clinical development as anticancer agents. In 
addition, we highlight the potential for implementation of 
these drugs in other pathological conditions, particularly 
in neuroinflammation.
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1  Introduction
It was recognized in the early 20th century that the growth 
of cancer cells and viruses could be stopped by interfering 
with their ability to utilize essential metabolites [1]. 
The advantages of this approach are simplicity and low 
price for synthesis of small molecules that resemble 
critical metabolites and thus interfere with the normal 
function of metabolic enzymes. Consequently, nucleotide 
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action achieved in anti-viral treatment could be partially 
due to alleviation of neuroinflammation [9]. In addition, 
apart from viruses and cancer cells, some of purine 
nucleoside analogues also target different cell types of 
immune system [11-13]. In the context of the foregoing and 
the fact that purine nucleoside analogues have ability to 
readily pass blood-brain barrier [14,15], administration 
of these substances expanded into neuropathological 
conditions associated with neuroinflammation. 
Herein, we describe the anticancer and neuroprotective 
action of certain purine nucleoside analogs initially 
developed as anticancer and antiviral drugs (Figure 1). A 
better understanding of their mechanism of action may 
provide the basis for the development of new compounds 
and contribute to the rational development of synergistic 
combinations with other drugs that have different and/or 
complementary mechanisms of action.
2  Mechanism of action of purine 
nucleoside analogs 
Purine nucleoside analogs enter cells through specific 
nucleoside transporters: concentrative and equilibrative 
nucleoside transporters [16]. Organic ion transporters 
as well as peptide transporters could be also involved 
in the cellular and viral uptake of certain analogs [17]. 
Once inside the cell, the nucleoside analog undergoes 
an initial rate-limiting phosphorylation step by a 
nucleoside kinase, which leads to the production of a 
monophosphate metabolite. A second phosphorylation 
step is then performed by nucleoside monophosphate 
kinase, and the third phosphorylation step is performed 
by nucleoside diphosphate kinase. Triphosphates 
can be incorporated in nucleic acids, in competition 
with endogenous nucleoside-triphosphates, or they 
can inhibit DNA and RNA synthesis by inhibiting 
essential enzymes such as polymerases [3]. In addition, 
ribonucleotide reductase M1 (RRM1), a key enzyme 
involved in nucleotide metabolism, can be inhibited both 
by diphosphorylated and triphosphorylated analogs. 
Catabolic enzymes may reduce the amount of active 
metabolites, including deaminases and 5ʹ-nucleotidases 
[3]. 
The incorporation into DNA may terminate the chain 
elongation, accumulate the mutations or induce DNA 
strand breaks and eventually lead to the apoptosis [18]. 
Nucleotide analogs compete with physiological 
nucleotides during the initiation and extension of DNA or 
RNA chains by cellular polymerases. The incorporation of 
the analogs is dependent on the affinity of polymerases 
for nucleotides [3]. Chain termination is observed with 
anticancer nucleotide analogs that possess the 3ʹ hydroxyl 
group (such as deoxyguanosine derivatives), and the 
recognition of the nucleotide as foreign seems to be 
responsible for this effect [3]. 
Figure 1. Chemical structure of purine nucleoside analogs with anticancer properties (a) 6-thioguanosine and (b) sulfinosine derived from 
6-thioguanosine; and neuroprotective properties (c) ribavirin and (d) tiazofurin.
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The sustained chain elongation after their incorporation 
into DNA or RNA may induce mismatching that leads to 
mutagenesis in human cells and viruses [19]. Although 
beneficial for the destruction of viruses, this is a serious 
obstacle for purine nucleoside usage in anticancer therapy. 
However, purine nucleoside analogs may induce 
apoptosis of cancer cells. The exact mechanism is still 
not clearly understood [18]. Nucleoside analogs generally 
cause a block in the S phase of the cell cycle due to the 
incorporation of their corresponding nucleotides in DNA 
chain. In contrast to other analogs, purine nucleoside 
analogs act both in the mitotic and quiescent cell cycle 
phases as the recognition of the inadequate nucleotides 
in DNA takes place only after second replication of the 
cell treated with purine nucleoside analog [3]. Therefore, 
they are commonly combined with DNA poisoning agents, 
such as alkylating or platinum compounds, as they both 
inhibit DNA repair [3].
3  Purine nucleoside analogs in 
anticancer research
3.1  Recently approved drugs and/or in 
clinical trials
There are only few FDA- and European Medicines Agency 
(EMA) - approved cytotoxic nucleoside analogs that are 
derivatives of deoxyadenosine or deoxyguanosine [20]. 
In the last few years, three deoxyadenosine have been 
approved for the treatment of lymphoid malignancies 
and other hematological disorders: cladribine or 
2-chlorodeoxyadenosine (2-CdA), fludarabine and 
pentostatin. 2-CdA and fludarabine are also active in the 
treatment of acute myeloid leukemia [21, 22]. Recently 
novel adenosine analog clofarabine has been introduced 
into clinical trials. It has been approved for the treatment 
of refractory patients with acute lymphoblastic leukemia 
and lymphoblastic lymphoma [23]. 
8-amino-adenosine that inhibits transcription and 
depletes adenosine-triphosphate (ATP) was in preclinical 
development [24, 25], while 8-chloro-adenosine was in 
phase I clinical trials [26]. Both 8-chloro-adenosine and 
8-amino-adenosine decrease RNA synthesis and induce 
cell death by decreasing the intracellular concentration of 
ATP [24]. 8-amino-adenosine induces a decrease in both 
RNA and DNA synthesis, whereas 8-chloro-adenosine 
preferentially decreases mRNA synthesis [25]. 8-chloro-
adenosine also inhibits the polymerization of actin and 
the activity of topoisomerase II [27, 28]. 
Controversial results have been obtained with cyclic 
nucleotide 8-chloro-cAMP that has been redrawn from 
Phase II clinical trials. Its action could be explained by 
modulation of protein kinase A activity [29] or through the 
conversion to its active nucleoside metabolite 8-chloro-
adenosine [26, 30]. 8-chloro-cAMP was shown to exert 
cytotoxic effect in a broad range of human cancer cell 
lines [31], disturb cell cycle kinetics and induce apoptosis 
in glioma and neuroblastoma cell lines [32, 33].
Very important findings indicated 8-Cl-cAMP as potent 
multidrug resistance reversal agent [34]. Pretreatment with 
8-Cl-cAMP improved the sensitivity to doxorubicin (DOX) 
more than verapamil (VER), the standard modulator of 
MDR. The increased accumulation of DOX observed after 
8-Cl-cAMP treatment resembled the results obtained with 
VER. Even more, 8-Cl-cAMP considerably decreased mdr1 
expression [34].
Nelarabine is a guanosine analog in which the 
hydrogen of the hydroxide group at the 6-position of 
the guanine ring is substituted by a methoxy group 
[35]. Nelarabine is more water soluble pro-drug of 
9-β-Darabinofuranosyl-guanine (Ara-G) [36]. The Ara-G 
competes with endogenous deoxynucleosides for 
incorporation into DNA by DNA polymerases. This results 
in inhibition of DNA synthesis and initiation of apoptosis 
[37].
3.2  Thiopurines
Particularly important group of the purine nucleoside 
analogs represents analogs with oxidized sulfur at the C6 
position. These compounds are known as thiopurines and 
their main representatives are 6-MP and 6-thioguanine 
(6-TG), clinically approved derivatives of hypoxantine 
and guanine, respectively [4]. Together with azathioprine 
(AZA), which is modified 6-MP, these thiopurines are used 
as immunomodulators in the treatment of inflammatory 
diseases [38-40], as well as anticancer agents, applied 
primarily in the treatment of acute leukemia [41, 42]. 
6-MP and 6-TG act as antimetabolites and exert their 
cytotoxic effect by interfering with purine metabolism. 
They are converted into the thioguanine nucleotides that 
compete with standard nucleotides and incorporate into 
DNA and RNA [43]. These false nucleotides are further 
targets for action of the mismatch repair (MMR) system 
[44]. Thiopurines can also lead to purine starvation by 
interfering with de novo purine synthesis [4].
Polymorphisms in enzymes involved in purine 
metabolism as well as alterations in components of 
DNA repair system and multidrug resistant associated 
proteins influence thiopurine cytotoxicity and can 
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lead to development of resistance to these drugs [45]. 
Moreover, prolonged treatment with thiopurines can lead 
to undesired side effects such as increased incidence of 
malignancies [46].Therefore, chemists were encouraged 
to develop new nucleoside analogs, which would have 
fewer side effects, better solubility and greater selectivity 
than 6-MP and 6-TG, and which could also successfully 
overcome resistance to 6-MP and 6-TG.
3.3  Sulfinosine, a derivative of 
6-thioguanosine
In 1990, a great number of new purine nucleosides 
were synthesized and tested for their antileukemic 
activity in mice. Sulfinosine or SF ([R,S]-2-amino-9-β-
D-ribofuranosylpurine-6-sulfinamide) was one of the 
most efficient newly synthesized compounds which was 
selected for further anticancer research. It is a thiopurine 
analog derived from 6-thioguanosine by amination 
with chloramine solution and subsequent oxidation 
[47]. First preclinical testing showed that SF was active 
against six solid tumors (glioma, sarcoma, melanoma, 
mammary and two colon carcinomas) and four strains of 
experimental leukemia, being more water soluble, dose 
and time dependent and having more cumulative effect 
than its precursor [48]. Most importantly, it was shown to 
be efficient against tumors resistant to other nucleoside 
analogs and cytotoxic drugs. SF was further used to 
synthesize other sulfur-containing cytotoxic drugs but 
they were not as effective as SF itself [49; 50].
SF inhibits cancer cell growth, at least partially, by the 
incorporation of its phosphorylated derivative into DNA. 
The metabolic conversion of SF into its corresponding 
nucleotide-monophosphate derivative is more complex 
than that of other thiopurines. Since SF utilizes different 
metabolic pathways for its intracellular activation, SF 
treatment does not induce resistance in cancer cells [51-
53].
After a decade of stagnation in SF research, studies 
on its anticancer activity were continued in 2002. Initially, 
this drug was shown to be effective against lung cancer, 
both non-small cell lung carcinoma (NSCLC) and small 
cell lung carcinoma (SCLC) cell lines in micromolar 
concentrations [54]. In this study SF was proved to disturb 
cell cycle kinetics and arrest cells in G2M phase further 
leading to extensive apoptosis. Additionally, SF was 
observed to exert cytotoxicity against neuroblastoma cells 
in a similar manner, also causing accumulation of cells 
in G2M phase and cell death by apoptosis [33]. Moreover, 
its antineoplastic activity against neuroblastomas was 
enhanced when combined with another cyclic purine 
nucleotide analog, 8-Cl-cAMP. Most notably, SF was 
nontoxic for normal cells (HaCaT), showing selectivity 
towards cancer cells [55].
A significant property of SF is its almost equal 
anticancer activity on both drug sensitive and their 
resistant counterparts with the overexpression of major 
multidrug resistant protein P-glycoprotein (P-gp). It can 
be successfully used to overcome multidrug resistance in 
NSCLC and glioma cell lines, either alone or in combination 
with other antineoplastic agents [34, 55-57]. Namely, SF 
efficiently inhibited cell growth, downregulated mdr1 and 
topo IIα gene expression and arrested cell cycle in S and G2M 
phase (Figure 2). These effects are even more pronounced 
and synergistic when SF was applied simultaneously with 
DOX or curcumine on resistant NSCLC cells [34, 57]. SF 
was also capable to induce apoptosis in p53-independent 
manner and to increase cellular autophagy [55]. 
Additionally, pretreatments with SF, either alone or with 
verapamil, could efficiently sensitize multidrug resistant 
cells to DOX treatment [34, 55, 58]. Treatment with SF prior 
to DOX, similarly to simultaneous treatment, efficiently 
reduced cell viability, decreased mdr1 and topo IIα gene 
expression and disturbed cell cycle kinetics in multidrug 
resistant cells [34, 58]. SF pretreatment increased DOX 
accumulation, similarly to non-competitive P-gp inhibitor 
tariquidar and even more than verapamil, a representative 
of first generation of P-gp competitive inhibitors [34, 
55, 58]. This purine nucleoside analog was proved to 
exert its antiangiogenic potential by modulating VEGF 
secretion and reducing its expression [55]. Additionally, it 
decreased the expression of HIF-1α, which was argued to 
be responsible for the anti-P-gp and anti-VEGF effects of 
SF [55].
The cellular redox environment is a delicate balance 
between the levels of reactive oxygen species (i.e., 
superoxide and hydrogen peroxide) and the antioxidant 
system that scavenges them (i.e., glutathione/glutathione 
peroxidase and tioredoxin/peroxiredoxin pathways) 
[59]. SF was capable to disturb significantly the redox 
balance in cancer cells (Figure 2). Namely, it was found 
that the mechanism of SF action against resistant tumors 
is essentially attributed to the significant depletion of 
glutathione (GSH) [55, 58]. Such effect on the cellular 
detoxification system is expected, since it was previously 
observed that SF readily and rapidly forms adducts 
with sulfhydryl compounds (GSH andcysteine) both in 
vivo and in vitro [51-53]. Furthermore, SF was shown to 
increase reactive oxygen species (ROS) and to inhibit the 
expression of key enzymes involved in GSH synthesis and 
cell detoxification, gamma glutamyl-cysteine-synthetase 
(γGCS)and glutathione-S-transferase π (gst-π) [55, 57]. The 
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alteration of gst-π expression was even more pronounced 
when resistant cells were co-treated with SF and curcumin 
[57].
Although poorly studied, purine nucleoside analog 
SF possesses unique anticancer effects. It depletes GSH 
and reverses multidrug resistant phenotypes through 
inhibition of P-gp expression and activity (Figure 2). 
The mechanisms beyond these effects are modification 
of redox status and HIF-1α regulation. These results 
rationalize the use of SF alone or in combination with 
conventional anticancer agents.
3.4  IMPDH inhibitors 
Ribavirin and tiazofurin are N-glycosyl and C-glycosyl 
purine nucleosides, respectively, both inhibitors of inosine 
5’-monophosphate dehydrogenase (IMPDH, EC 1.1.1.205), 
a key enzyme of de novo guanosine-5’-triphosphate 
(GTP) biosynthesis (Figure 3). Inhibition of IMPDH 
lowers the cellular guanine nucleotide concentration 
and as a consequence interruption of GTP-dependent 
cellular processes occurs, which could result in antiviral, 
anticancer or immunosuppressive activity[60]. It should 
be noted that ribavirin and tiazofurin achieve most of 
their biological action through their active metabolites. 
Ribavirin is metabolized to ribavirin-monophosphate, 
-diphosphate and –triphosphate and tiazofurin into 
tiazole-4-carboxamide adenine dinucleotide.
Since IMPDH was recognized as an enzyme linked 
with proliferation and malignancy [61], ribavirin and 
tiazofurin activity against numerous cancer cell lines was 
proved. Both compounds reached Phase II of clinical trials 
against leukemia [62, 63]. Patients with bcr-abl positive 
acute myelogenous leukemia and chronic myelogenous 
leukemia in blast crisis treated with tiazofurin achieved 
transient hematologic responses [63]. Chemotherapy of 
leukemia with tiazofurin is based on the inhibition of 
IMPDH enzyme since it was shown that up-regulation 
of this enzyme together with the p210 bcr-abl gene 
rearrangement is a feature of chronic myelogenous 
leukemia [64]. Ribavirin also showed encouraging activity 
against M4/M5 subtypes of acute myelogenous leukemia 
Figure 2. The effects of purine nucleoside analog - sulfinosine (SF) on mdr1 expression and intracellular redox status. Although many chemo-
therapeutics generate reactive oxygene species (ROS), SF is able to deplete glutathione (GSH) partly by down-regulation of the key enzyme 
for GSH synthesis (γGCS) and suppress intracellular detoxification. Besides that, SF in its metabolized form may arrest cell cycle in S and/or 
G2/M phase and induce apoptosis. Although conventional chemotherapeutics often up-regulate mdr1 expression and consequently induce 
P-glycoprotein (P-gp) expression, SF down-regulates both the mdr1 and P-gp expression. These effects SF exerts indirectly by depletion of 
GSH and down-regulation of HIF1-α.
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[62, 65]. Unlike tiazofurin, the chemotherapeutic target 
of ribavirin is not IMPDH. It entails acting on another 
molecule - the eukaryotic translation initiation factor 
eIF4E, which is shown to be elevated in M4/M5 acute 
myelogenous leukemia [66] that could be blocked by 
ribavirin [67]. These results indicated that ribavirin and 
tiazofurin are good candidates for combination treatments 
with already established antileukemia therapeutics.
In vitro studies showed considerable antiglioma and 
antiangiogenic activity of tiazofurin [68, 69].
4  Purine nucleoside analogs in 
neuroinflammation
From the time when ribavirin was synthesized in 1972 as 
broad spectrum antiviral agent, its clinical application was 
limited against two infections, one caused by Hepatitis C 
virus (HCV) and the other by Respiratory syncytial virus 
(RSV) [70-75]. In the treatment of chronic HCV infection, it 
is necessary to emphasize that the ribavirin is administered 
in combination with other approved therapies (e.g. 
peginterferon alfa-2a), since it was not effective as 
monotherapy. Although ribavirin antiviral activity is well 
known, the precise mechanism that lies underneath is 
not yet fully elucidated, probably because ribavirin does 
not universally act on all viruses; its actions are rather 
virus specific and also depend on the type of infected cell 
[76]. Ribavirin antiviral activity depends on its interaction 
with viral RNA polymerases that lead to inhibition of viral 
replication or to error catastrophe incident, although it is 
not excluded that in certain cases the antiviral effect can 
be achieved via inhibition of IMPDH [76]. Since tiazofurin 
is known only as potent and selective IMPDH inhibitor this 
could be the reason why tiazofurin has a narrower circle 
of action when it comes to viruses compared to ribavirin 
[77, 78].
4.1  Experimental autoimmune 
encephalomyelitis
Recent studies repositioned ribavirin and tiazofurin in 
the field of neuroinflammation, more precisely, to animal 
model of multiple sclerosis – experimental autoimmune 
encephalomyelitis (EAE). How did it come to these 
investigations? The first important fact was that ribavirin 
Figure 3. IMPDH is a crucial in de novo guanosine-5’-triphosphate (GTP) biosynthesis. IMPDH converts inosine 5’-monophosphate (IMP) to 
xanthosine 5’- monophosphate (XMP) using nicotinamide adenine dinucleotide (NAD+) as a cofactor. Ribavirin 5’-monophosphate (RMP - 
active metabolite of ribavirin) blocks the enzyme at the IMP binding site. Tiazofurin is anabolized intracellularly to tiazole-4-carboxamide 
adenine dinucleotide (TAD) which tightly bounds to NAD site. IMPDH inhibition by ribavirin and tiazofurin leads to a depletion of the guanine 
nucleotide pool and consequent attenuation of GTP-dependent cellular processes and is related with their anti-tumor and immunosuppres-
sive action.
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has the capacity to enter the CNS, where it demonstrated 
antiviral activity against several RNA viruses responsible 
for neurological damage in humans and animals [79-81]. 
In addition, ribavirin entry in the brain is enhanced by 
neuroinflammation, due to disrupted blood brain barrier 
(BBB)[15]. Likewise, tiazofurin has ability to cross the 
BBB [14, 82]. The second important fact was that IMPDH 
inhibitors exhibit immunosuppressive actions [83, 84]. In 
addition, it was shown that ribavirin inhibits proliferation 
of human peripheral blood lymphocytes and preserves 
Th1 cytokine production [85], but inhibits Th2 cytokine 
response in viral-induced macrophages [11].
Potential immunosuppressive actions of ribavirin and 
tiazofurin, together with the ability to enter the CNS, have 
encouraged research of these drugs in the EAE, which 
started a decade ago.  Both drugs proved to be efficient in 
the amelioration of disease severity regardless of whether 
they were administrated from inductive (day 0) or effective 
phase (day 7) of EAE [86, 87]. Since this neurodegenerative 
disorder implies disturbance of balance between the 
immune system and the CNS, these beneficial effects of 
ribavirin and tiazofurin raised question: which system of 
these two is their main target?
Stosic-Grujicic et al. placed effects of tiazofurin outside 
the CNS, demonstrating that this drug manly affects the 
immune branch of disease, through interaction with 
encephalitogenic T-cells [87]. However, the well known 
anti-proliferative action of tiazofurin in malignancy 
was not confirmed on autoreactive T-cells in EAE. Based 
on reduced intensity of adhesion interactions between 
mononuclear cells isolated from tiazofurin treated 
animals recorded in vitro and reduced mononuclear cell 
infiltration in the spinal cord of tiazofurin treated rats, 
it was concluded that this drug interferes with adhesive 
interaction between encephalitogenic T-cells and 
endothelial cells of brain vasculature, and thus prevents 
lymphocytes to enter into the CNS. An explanation of 
aforementioned has been found in the inhibition of 
IMPDH. The inhibition of IMPDH enzyme leads to a 
depletion of cellular GTP pool and several studies on 
lymphocytes and monocytes with other IMPDH inhibitors 
have shown that lack of GTP suppresses glycosylation of 
adhesion molecules on these cells and thus prevents their 
binding function [83]. Therefore, it was concluded that 
this may be the reason why tiazofurin induced favorable 
disease outcome.
The first study on the role of ribavirin in EAE was 
published a year later with a focus on histopathological 
changes within the CNS [80]. Namely, ribavirin induced 
general reduction of inflammatory infiltrates (CD4+ and 
CD8+ T cells as well as macrophages, monocytes and 
granulocytes), prevented demyelination and decreased 
microgliosis in spinal cord of diseased animals. 
Nevertheless, as for the tiazofurin, explanation for 
attenuated histological signs in spinal cord of EAE animals 
was also found in preventing lymphocyte recruitment 
into the target tissue, a process linked to interference 
with adhesion interactions between cells. The concept 
that nucleoside analogs operate mainly outside of the 
CNS in EAE pathology was further confirmed by the 
study of Lavrnja et al. in 2008 [88]. It was shown that 
aside from limiting the entrance of autoreactive T-cells 
into the CNS, ribavirin also substantially reduced levels 
of proinflammatory cytokines (IFN-γ, IL 1-β and TNF-α) 
produced by immune cells in draining lymph node in 
initial phase of EAE. Consequently, expression of IFN-γ, 
IL1-β and TNF-α was down-regulated in the spinal cord 
tissue at the pick and the end of disease.
Several studies exploited the fact that ribavirin and 
tiazofurin inhibit IMPDH via their active metabolites 
through binding to the enzyme at different sites and 
trialed them in combination therapy [89-91]. Indeed, it 
was shown that combination therapy was more effective 
in suppression of the ongoing disease, than each drug 
used alone. 
4.2  Modulation of glial cell response
The effect of ribavirin and tiazofurin was also studied 
on glial cells obtained from rat CNS. It was shown that 
ribavirin reduced the number of reactive astrocytes in 
the white and grey matter of the spinal cord, probably via 
affecting proliferation of these cells [92]. These data are 
consistent with our previous reports showing that ribavirin 
down-regulates the process of reactive astrogliosis and 
postpones glial scarring after adult brain injury, even after 
the cessation of treatment [93, 94]. Apart of its effects on 
GTP biosynthesis pathway, ribavirin was shown to affect 
the ERK/MAPK signaling pathway that is known to be 
essential for the induction and maintenance of reactive 
astroglial phenotypes. Namely, Pekovic et al. revealed that 
ribavirin attenuates ERK1/2 expression around the lesion 
site and hypothesized that down-regulation of ERK-MAPK 
signaling pathway underlies the inhibition of reactive 
astrogliosis in the rat forebrain following stab injury 
[94]. Besides, in EAE, ribavirin together with tiazofurin, 
polarized morphology of microglia and astrocytes to a less 
activated state, that indicated attenuation of inflammation 
in the spinal cord [92, 95]. Certainly, the modulation of 
glial cell response during EAE may be due to preventing 
infiltration of immune cells in the CNS. However, the 
fact that ribavirin regulated glial fibrillary acidic protein, 
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In the case of anticancer purine nucleoside 
analogs, approved compounds remain largely limited to 
hematological malignancies [20]. Their potential in the 
therapy of solid malignancies is not sufficiently explored. 
Therefore, this field would greatly benefit from an improved 
knowledge about the role of purine nucleoside analogs in 
cancer metabolism and chemoresistance. According to 
our results, patients with incurable neurodegenerative 
diseases and chemoresistant gliomas may both benefit 
from therapy based on purine nucleoside analogs. 
Although the idea to use purine (as well as pyrimidine) 
vimentin and TNF-α expression at the mRNA level in 
spinal cord tissue indicated that they might act on the 
other side of the BBB (i.e. within the CNS) [92].
In addition, the theory that they can operate within 
the CNS has been further strengthened by the study of 
their effect on cultured microglia cells, specifically in in 
vitro model of neuroinflammation [96, 97]. Ribavirin and 
tiazofurin modulated the activity of immune-stimulated 
microglia in a complex manner inducing both anti- and 
pro-inflammatory effects. Anti-inflammatory modulation 
of microglia activity included a reduction in cell viability 
and NO level, suppression of the activated morphological 
profile of microglia, reduction in TNF-α and IL-6 release, 
as well as an increase in IL-10 secretion. Conversely, 
enhanced release of IL-1β represented pro-inflammatory 
property of ribavirin and tiazofurin [96, 97]. These 
results could be placed into the context of ribavirin use 
as antiviral agent and tiazofurin as an anticancer drug. 
Since HCV virus could activate microglial cells, which 
may induce irreversible neurological damage [98, 99], 
there is a possibility that part of ribavirin therapeutic 
action achieved in HCV treatment could be due to its 
effect on microglial cells. Tiazofurin anticancer activity 
was demonstrated on various neoplastic cells, including 
glioma cell lines [68, 100]. Since microglia cells could 
be significant for progression or suppression of glioma 
[101], the fact that tiazofurin affects both of these cell 
types makes this drug interesting for future surveys that 
investigate interactions of microglial and glioma cells. 
In general, although ribavirin and tiazofurin have 
capacity to interact with cells of immune system, as well 
as with cells of the CNS, they affect more powerfully 
immune branch of EAE, probably because immune cells 
are more sensitive to IMPDH inhibition (Figure 4).
4.3  Potential of purine nucleoside analogs 
for medicinal usage 
Besides their role in oncology and virology, some 
analogs have been used in various other indications 
such as immunosuppression (azathioprine, a derivative 
of 6-MP), neuroprotection and cardioprotection [92, 95, 
102]. Interestingly, several purine nucleoside analogs 
have undergone drug repurposing. For example, ribavirin 
that was initially approved as antiviral agents has shown 
promising antileukemia properties [66]. Similarly, 
certain anticancer analogs have been found to possess 
antiviral or antibacterial properties. In some instances, 
agents (ribavirin and tiazofurin) have been repositioned 
to non-viral and non-cancer indications such as 
neurodegenerative diseases or brain injuries [86, 87, 94].
Figure 4. Possible targets of ribavirin (RBV) and tiazofurin (TR) in 
EAE. The main beneficial effect of these purine nucleoside ana-
logues is achieved on periphery by impeding infiltration of activated 
T-lymphocyte into the CNS via obstructing adhesive interaction 
between T-cells and endothelial cells of the BBB (shown in blood 
vessel). RBV and TR enter the CNS via nucleoside transporters (NT) 
or through disrupted BBB. In the CNS, RBV and TR modulate reactive 
astrocytes and activated microglia towards a more quiescent state. 
Moreover, they reduce the number of activated microglia that 
include microglial cells which have the function of antigen presen-
ting cells (APC), required for reactivation of T-cells within the CNS.
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analogs is old, it should not be underestimated. These 
drugs certainly deserve to be more exploited as therapeutic 
agents.
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